WEBULL
News
IMA
5.84
-3.31%
-0.20
Weekly Report: what happened at IMA last week (0223-0227)?
Weekly Report · 5d ago
ImageneBio to Participate in Leerink Global Healthcare Conference
Reuters · 02/26 13:03
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/25/26
TipRanks · 02/25 13:36
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
TipRanks · 02/24 14:04
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
TipRanks · 02/23 15:55
Weekly Report: what happened at IMA last week (0216-0220)?
Weekly Report · 02/23 10:21
ImageneBio Inc. Files Initial Beneficial Ownership Statement for Chief Medical Officer Benjamin Porter-Brown
Reuters · 02/20 21:20
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
TipRanks · 02/20 18:50
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
TipRanks · 02/19 13:40
ImageneBio announces immediate resignation of board director
TipRanks · 02/17 23:04
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/16/26
TipRanks · 02/16 13:03
Weekly Report: what happened at IMA last week (0209-0213)?
Weekly Report · 02/16 10:21
Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26
TipRanks · 02/13 16:15
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/12/26
TipRanks · 02/12 15:56
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/11/26
TipRanks · 02/11 14:12
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/10/26
TipRanks · 02/10 13:14
ImageneBio appoints Ben Porter-Brown as Chief Medical Officer
TipRanks · 02/10 12:21
*ImageneBio Appoints Ben Porter-Brown as Chief Medical Officer >IMA
Dow Jones · 02/10 12:02
ImageneBio Names Dr. Ben Porter-Brown as Chief Medical Officer
Reuters · 02/10 12:00
Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Dow Jones · 02/10 12:00
More
Webull provides a variety of real-time IMA stock news. You can receive the latest news about ImageneBio through multiple platforms. This information may help you make smarter investment decisions.
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.